Cytochrome P-450 2D6 (CYP2D6) Genotype and Breast Cancer Recurrence in Tamoxifen-Treated Patients: Evaluating the Importance of Loss of Heterozygosity
Authors:
- Thomas P. AhernTAThomas P. Ahern
- Daniel L. HertzDHDaniel L. Hertz
- Per DamkierPDPer Damkier
- Bent EjlertsenBEBent Ejlertsen
- Stephen J. Hamilton-DutoitSHStephen J. Hamilton-Dutoit
- James M. RaeJRJames M. Rae
- Meredith M. ReganMRMeredith M. Regan
- Alastair M. ThompsonATAlastair M. Thompson
- Timothy L. LashTLTimothy L. Lash
- Deirdre P. Cronin-FentonDCDeirdre P. Cronin-Fenton
Open Access
- 17 December 2016
- journal article
- research article
- Published by Oxford University Press (OUP) in American Journal of Epidemiology
- Vol. 185 (2) , 75-85
Abstract
Tamoxifen therapy for estrogen receptor–positive breast cancer reduces the risk of recurrence by approximately one-half. Cytochrome P-450 2D6, encoded by the polymorphic cytochrome P-450 2D6 gene (CYP2D6), oxidizes tamoxifen to its most active metabolites. Steady-state concentrations of endoxifen (4-hydroxy-N-desmethyltamoxifen), the most potent antiestrogenic metabolite, are reduced in women whose CYP2D6 genotypes confer poor enzyme function. Thirty-one studies of the association of CYP2D6 genotype with breast cancer survival have yielded heterogeneous results. Some influential studies genotyped DNA from tumor-infiltrated tissues, and their results may have been susceptible to germline genotype misclassification from loss of heterozygosity at the CYP2D6 locus. We systematically reviewed 6 studies of concordance between genotypes obtained from paired nonneoplastic and breast tumor–infiltrated tissues, all of which showed excellent CYP2D6 genotype agreement. We applied these concordance data to a quantitative bias analysis of the subset of the 31 studies that were based on genotypes from tumor-infiltrated tissue to examine whether genotyping errors substantially biased estimates of association. The bias analysis showed negligible bias by discordant genotypes. Summary estimates of association, with or without bias adjustment, indicated no clinically important association between CYP2D6 genotype and breast cancer survival in tamoxifen-treated women.Keywords
Funding Information
- National Institutes of Health (R01 CA118708, R01 CA166825, R01GM099143)
- Danish Cancer Society (DP06117)
- Lundbeck Foundation (R167-2013-15861)
- Susan G. Komen for the Cure (CCR13264024, KG080081)
- Breast Cancer Research Foundation (N003173)
- Breast Cancer Campaign
- Mary Kay Ash Foundation (003-14)
This publication has 87 references indexed in Scilit:
- Association of CYP2D6 and CYP2C19 polymorphisms and disease-free survival of Thai post-menopausal breast cancer patients who received adjuvant tamoxifenPharmacogenomics and Personalized Medicine, 2013
- Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trialThe Lancet, 2013
- Clinical and biomarker predictors of side effects from tamoxifenBreast Cancer Research and Treatment, 2011
- Strategies for subtypes—dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011Annals of Oncology, 2011
- Tamoxifen Metabolite Concentrations, CYP2D6 Genotype, and Breast Cancer OutcomesClinical Pharmacology & Therapeutics, 2011
- Early discontinuation and non-adherence to adjuvant hormonal therapy are associated with increased mortality in women with breast cancerBreast Cancer Research and Treatment, 2010
- Genotype-guided tamoxifen therapy: time to pause for reflection?The Lancet Oncology, 2009
- Cytochrome P450 2D6 activity predicts discontinuation of tamoxifen therapy in breast cancer patientsThe Pharmacogenomics Journal, 2009
- Tamoxifen: Catalyst for the change to targeted therapyEuropean Journal of Cancer, 2008
- Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trialsThe Lancet, 2005